Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment. The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was ...
After hours: February 28 at 7:54:42 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback